Eli Lilly will acquire the AbbVie-backed neurological disease therapy developer in a $135m transaction that could top $1.2bn with milestone payments.

Instylla, developer of a blood-flow control system, has completed a $25.4m series B round featuring returning investor Ascension Ventures.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

SoftBank has exited the electronic health record platform through a $32.7m acquisition by medical school operator Afya.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.

The federal development board for Southern Ontario has injected $5m to accelerate the growth potential of TIAP's early-stage health sciences portfolio.

Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The personalised medicine technology provider hiked its overall funding to $115m, with Cardinal Health, McKesson Ventures and Novartis all backing a series C extension.